PleoPharma Announces 1st Patient Dosed in Phase 3 Clinical Trial for Cannabis Use Disorder
#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
This Phase 3 trial represents progress toward a potential FDA-approved medication for cannabis use disorder, which affects approximately 9% of cannabis users and currently lacks pharmacological treatment options. Clinicians treating patients with cannabis dependence could gain an evidence-based pharmaceutical tool to complement behavioral interventions if the trial demonstrates efficacy and safety. For patients seeking help with cannabis use disorder, an approved medication would expand treatment access beyond existing psychosocial approaches and may improve outcomes for those who prefer or need pharmacological support.
PleoPharma has initiated a Phase 3 clinical trial evaluating hemp-derived cannabinoids for cannabis use disorder, marking a significant advancement in pharmacological treatment development for this condition. This trial represents the first large-scale, late-stage efficacy study of cannabinoid-based therapy for cannabis dependence, a disorder that affects millions globally and currently lacks FDA-approved medications. The progression to Phase 3 suggests preliminary safety and efficacy data from earlier trials were sufficient to support further investigation, though detailed results from Phase 1 and 2 studies are not described in this announcement. For clinicians, successful completion of this trial could provide the first pharmaceutical option to offer patients struggling with cannabis dependence, potentially reducing relapse rates and withdrawal symptoms that complicate cessation efforts. If approved, a hemp-derived cannabinoid product would represent an important addition to the limited behavioral and psychosocial interventions currently available for cannabis use disorder. Clinicians should monitor the results of this Phase 3 trial as it may eventually expand treatment options for a patient population with significant unmet medical needs.
“We’re at an early stage with this Phase 3 trial, so I’m watching carefully but won’t draw clinical conclusions until we have the complete data and peer-reviewed publication. Cannabis use disorder is a real clinical problem that deserves rigorous investigation, and if this cannabinoid-based approach shows efficacy and safety in the full trial, it could meaningfully expand our treatment options.”
💊 The initiation of a Phase 3 trial for a cannabis use disorder treatment represents a meaningful development in addressing a condition that affects millions globally, yet remains challenging to treat in clinical settings. While this advancement signals potential therapeutic options beyond behavioral interventions and psychosocial support, clinicians should recognize that the efficacy and safety profile of hemp-derived cannabinoids for this indication remain uncertain pending trial completion and regulatory review. Important caveats include the heterogeneity of cannabis use patterns among patients, potential drug-drug interactions with commonly prescribed medications, and the lack of long-term safety data specific to this population. Additionally, patients may harbor skepticism about cannabinoid-based treatments given the lay association between cannabinoids and cannabis itself. Providers should stay informed about trial outcomes and regulatory decisions while continuing to offer evidence-based interventions, and consider potential pharmacologic options such as these only when integrated within comprehensive treatment plans that address underlying psychiatric and psych
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Read next
